Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy product candidate is AR101, an investigational biologic for the treatment of patients with peanut allergy. The company has strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics. The company was formerly known as Allergen Research Corporation and changed its name to Aimmune Therapeutics, Inc. in May 2015. Aimmune Therapeutics, Inc. was founded in 2011 and is headquartered in Brisbane, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone650-614-5220
Debt
Current Ratio6.99
Quick Ratio6.99
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Price / Cash FlowN/A
Price / Book6.78
Profitability
Net Income$-131,320,000.00
Net MarginsN/A
Return on Assets-65.91%
Miscellaneous
Employees131
OptionableOptionable
Aimmune Therapeutics (NASDAQ:AIMT) Frequently Asked Questions
What is Aimmune Therapeutics' stock symbol?
Aimmune Therapeutics trades on the NASDAQ under the ticker symbol "AIMT."
How were Aimmune Therapeutics' earnings last quarter?
Aimmune Therapeutics Inc (NASDAQ:AIMT) issued its quarterly earnings data on Thursday, November, 8th. The biotechnology company reported ($0.89) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.92) by $0.03. View Aimmune Therapeutics' Earnings History.
When is Aimmune Therapeutics' next earnings date?
What price target have analysts set for AIMT?
9 Wall Street analysts have issued 12-month price objectives for Aimmune Therapeutics' shares. Their forecasts range from $30.00 to $80.00. On average, they anticipate Aimmune Therapeutics' stock price to reach $50.5567 in the next twelve months. This suggests a possible upside of 113.0% from the stock's current price. View Analyst Price Targets for Aimmune Therapeutics.
What is the consensus analysts' recommendation for Aimmune Therapeutics?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aimmune Therapeutics in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aimmune Therapeutics.
What are Wall Street analysts saying about Aimmune Therapeutics stock?
Here are some recent quotes from research analysts about Aimmune Therapeutics stock:
- 1. According to Zacks Investment Research, "Aimmune Therapeutics, Inc. is a biopharmaceutical company which is engaged in the development of desensitization treatments for peanut and other food allergies. The Company's characterized oral desensitization immunotherapy includes AR101, a product for the treatment of peanut allergy in children and adults which is in clinical trial stage. Aimmune Therapeutics, Inc. is headquartered in Brisbane, California. " (1/14/2019)
- 2. Cantor Fitzgerald analysts commented, ". We are assuming coverage of AIMT with an Overweight rating and a 12-month PT of $64 based on lead asset AR101 in peanut allergy. Given the growing unmet clinical need in PA, ‘101 has Track designations, and we believe a high regulatory PoS exists based on data from the P3 PALISADE study. Full study data were recently published in the NEJM, validating the results and further enhancing our conviction given the notably reduced use of rescue epinephrine during the DBPCFC and limited use during updosing." (12/2/2018)
Has Aimmune Therapeutics been receiving favorable news coverage?
News coverage about AIMT stock has been trending somewhat positive on Tuesday, according to InfoTrie Sentiment. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Aimmune Therapeutics earned a news sentiment score of 1.9 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the next several days.
Who are some of Aimmune Therapeutics' key competitors?
Some companies that are related to Aimmune Therapeutics include SAGE Therapeutics (SAGE), Amarin (AMRN), GALAPAGOS NV/S (GLPG), Alkermes (ALKS), United Therapeutics (UTHR), Catalent (CTLT), TESARO (TSRO), FibroGen (FGEN), Amneal Pharmaceuticals (AMRX), GW Pharmaceuticals PLC- (GWPH), Array Biopharma (ARRY), Taro Pharmaceutical Industries (TARO), Horizon Pharma (HZNP), Evotec (EVTCY) and Emergent Biosolutions (EBS).
Who are Aimmune Therapeutics' key executives?
Aimmune Therapeutics' management team includes the folowing people:
- Mr. Eric H. Bjerkholt, Chief Financial Officer (Age 59)
- Mr. Jeffrey H. Knapp, Chief Operating Officer (Age 53)
- Mr. Douglas T. Sheehy, Gen. Counsel & Sec. (Age 52)
- Dr. Daniel C. Adelman, Chief Medical Officer (Age 62)
- Dr. Stephen George Dilly, Special Advisor (Age 59)
When did Aimmune Therapeutics IPO?
(AIMT) raised $124 million in an initial public offering (IPO) on Thursday, August 6th 2015. The company issued 8,300,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Credit Suisse and Piper Jaffray served as the underwriters for the IPO.
Who are Aimmune Therapeutics' major shareholders?
Aimmune Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Taylor Wealth Management Partners (0.01%) and Carroll Financial Associates Inc. (0.00%). Company insiders that own Aimmune Therapeutics stock include Bakker Juliet Tammenoms, Daniel C Md Adelman, Douglas T Sheehy, Eric Bjerkholt, Jayson Donald Alexander Dallas, Kathryn E Falberg, Mary M Rozenman, Patrick G Enright, Stephen George Dilly, Susan E Barrowcliffe and Warren L Desouza. View Institutional Ownership Trends for Aimmune Therapeutics.
Which major investors are selling Aimmune Therapeutics stock?
AIMT stock was sold by a variety of institutional investors in the last quarter, including Taylor Wealth Management Partners. Company insiders that have sold Aimmune Therapeutics company stock in the last year include Daniel C Md Adelman, Douglas T Sheehy, Mary M Rozenman and Stephen George Dilly. View Insider Buying and Selling for Aimmune Therapeutics.
Which major investors are buying Aimmune Therapeutics stock?
AIMT stock was purchased by a variety of institutional investors in the last quarter, including Carroll Financial Associates Inc.. Company insiders that have bought Aimmune Therapeutics stock in the last two years include Bakker Juliet Tammenoms, Eric Bjerkholt, Jayson Donald Alexander Dallas, Kathryn E Falberg and Patrick G Enright. View Insider Buying and Selling for Aimmune Therapeutics.
How do I buy shares of Aimmune Therapeutics?
Shares of AIMT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Aimmune Therapeutics' stock price today?
One share of AIMT stock can currently be purchased for approximately $23.73.
How big of a company is Aimmune Therapeutics?
Aimmune Therapeutics has a market capitalization of $1.51 billion. The biotechnology company earns $-131,320,000.00 in net income (profit) each year or ($2.61) on an earnings per share basis. Aimmune Therapeutics employs 131 workers across the globe.
What is Aimmune Therapeutics' official website?
How can I contact Aimmune Therapeutics?
Aimmune Therapeutics' mailing address is 8000 MARINA BOULEVARD SUITE 300, BRISBANE CA, 94005. The biotechnology company can be reached via phone at 650-614-5220 or via email at [email protected]
MarketBeat Community Rating for Aimmune Therapeutics (NASDAQ AIMT)
MarketBeat's community ratings are surveys of what our community members think about Aimmune Therapeutics and other stocks. Vote "Outperform" if you believe AIMT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AIMT will underperform the S&P 500 over the long term. You may vote once every thirty days.
